Reuters -- GlaxoSmithKline's (GSK.L) breast cancer drug Tyverb has been rejected once again by Britain's cost watchdog NICE. The National Institute for Health Clinical Excellence (NICE), which assesses drugs for reimbursement, said on Wednesday the drug's limited benefit and high price meant it was not suitable for use on the state health service.
